Irini Gerogianni
University of Thessaly
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Irini Gerogianni.
American Journal of Respiratory and Critical Care Medicine | 2014
Martina Sester; Frank van Leth; Judith Bruchfeld; Dragos Bumbacea; Daniela M. Cirillo; Asli Gorek Dilektasli; J. Domínguez; Raquel Duarte; Martin Ernst; Fusun Oner Eyuboglu; Irini Gerogianni; Enrico Girardi; Delia Goletti; Jean-Paul Janssens; Inger Julander; Berit Lange; Irene Latorre; Monica Losi; Roumiana Markova; Alberto Matteelli; Heather Milburn; Pernille Ravn; Theresia Scholman; Paola M. Soccal; Marina Straub; Dirk Wagner; Timo Wolf; Aslihan Yalcin; Christoph Lange
RATIONALE In the absence of active tuberculosis, a positive tuberculin skin test (TST) or interferon-γ release assay (IGRA) result defines latent infection with Mycobacterium tuberculosis, although test results may vary depending on immunodeficiency. OBJECTIVES This study compared the performance of TST and IGRAs in five different groups of immunocompromised patients, and evaluated their ability to identify those at risk for development of tuberculosis. METHODS Immunocompromised patients with HIV infection, chronic renal failure, rheumatoid arthritis, solid-organ or stem-cell transplantation, and healthy control subjects were evaluated head-to-head by the TST, QuantiFERON-TB-Gold in-tube test (ELISA), and T-SPOT.TB test (enzyme-linked immunospot) at 17 centers in 11 European countries. Development of tuberculosis was assessed during follow-up. MEASUREMENTS AND MAIN RESULTS Frequencies of positive test results varied from 8.7 to 15.9% in HIV infection (n = 768), 25.3 to 30.6% in chronic renal failure (n = 270), 25.0% to 37.2% in rheumatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 15.2% in immunocompetent control subjects (n = 211). Eleven patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis during a median follow-up of 1.8 (interquartile range, 0.2-3.0) years. Six of the 11 patients had a negative or indeterminate test result in all three tests at the time of screening. Tuberculosis incidence was generally low, but higher in HIV-infected individuals with a positive TST (3.25 cases per 100 person-years) than with a positive ELISA (1.31 cases per 100 person-years) or enzyme-linked immunospot result (1.78 cases per 100 person-years). No cases of tuberculosis occurred in patients who received preventive chemotherapy. CONCLUSIONS Among immunocompromised patients evaluated in this study, progression toward tuberculosis was highest in HIV-infected individuals and was poorly predicted by TST or IGRAs. Clinical trial registered with www.clinicaltrials.gov (NCT 00707317).
Tuberculosis | 2011
Morten Ruhwald; J. Domínguez; Irene Latorre; Monica Losi; Luca Richeldi; Maria Bruna Pasticci; Rosanna Mazzolla; Delia Goletti; Ornella Butera; Judith Bruchfeld; Hans Gaines; Irini Gerogianni; Tamara Tuuminen; Giovanni Ferrara; Jesper Eugen-Olsen; Pernille Ravn
IP-10 has potential as a diagnostic marker for infection with Mycobacterium tuberculosis, with comparable accuracy to QuantiFERON-TB Gold In-Tube test (QFT-IT). The aims were to assess the sensitivity and specificity of IP-10, and to evaluate the impact of co-morbidity on IP-10 and QFT-IT. 168 cases with active TB, 101 healthy controls and 175 non-TB patients were included. IP-10 and IFN-γ were measured in plasma of QFT-IT stimulated whole blood and analyzed using previously determined algorithms. A subgroup of 48 patients and 70 healthy controls was tested in parallel with T-SPOT.TB IP-10 and QFT-IT had comparable accuracy. Sensitivity was 81% and 84% with a specificity of 97% and 100%, respectively. Combining IP-10 and QFT-IT improved sensitivity to 87% (p < 0.0005), with a specificity of 97%. T-SPOT.TB was more sensitive than QFT-IT, but not IP-10. Among non-TB patients IP-10 had a higher rate of positive responders (35% vs 27%, p < 0.02) and for both tests a positive response was associated with relevant risk factors. IFN-γ but not IP-10 responses to mitogen stimulation were reduced in patients with TB and non-TB infection. This study confirms and validates previous findings and adds substance to IP-10 as a novel diagnostic marker for infection with M. tuberculosis. IP-10 appeared less influenced by infections other than TB; further studies are needed to test the clinical impact of these findings.
Respirology | 2006
Anargyros N. Moulas; Irini Gerogianni; Dimitrios Papadopoulos; Konstantinos Gourgoulianis
Objectives:: Epidemiological studies have shown an inverse relationship between dietary vitamin A intake and the risk of developing lung cancer. The aim of this study was to investigate the vitamin A status in patients with lung cancer, by determining the serum levels of retinoic acid, retinol and retinyl palmitate.
Respirology | 2008
Irini Gerogianni; Maria Papala; Dimitra Klapsa; Elias Zinzaras; Efi Petinaki; Kostas I. Gourgoulianis
Background and objective: Although QuantiFERON‐TB Gold (QFT‐G) has been approved for the diagnosis of latent tuberculosis infection (LTBI), there are limited data regarding its performance in routine clinical practice. The aim of this study was to compare QFT‐G ‘In Tube’ results, based on stimulation with Mycobacterium tuberculosis‐specific antigens, with tuberculin skin test (TST) results in an unselected hospital‐based Greek population.
International Urology and Nephrology | 2008
Irini Gerogianni; Stavros Gravas; Dimitrios Papadopoulos; Anastassios Terzis; Maria Nakou; Vassilios Tzortzis; Konstantinos Gourgoulianis; Michael D. Melekos
We report a case of endobronchial metastasis from prostate adenocarcinoma. A patient with a history of prostate cancer under complete androgen blockade presented to the respiratory department complaining of dyspnea and dry coughing. Flexible bronchoscopy showed multiple polypoid lesions in the tracheobronchial tree and the immunohistochemical studies on the biopsy specimen determined the diagnosis. The patient was treated with paclitaxel, estramustine phosphate and carboplatine, and experienced symptoms suppression. To our knowledge, this is the first case of endobronchial metastasis of a patient with androgen refractory prostate cancer without any evidence of extrathoracic metastasis. The current report also emphasises the need for a multidisciplinary approach for cases of endobronchial metastases, with the collaboration of pneumologists, urologists, pathologists and oncologists.
Scandinavian Journal of Infectious Diseases | 2007
Christoforos N. Foroulis; Irini Gerogianni; Vassilios K. Kouritas; Eleni Karestsi; Dimitra Klapsa; Konstantinos Gourgoulianis; Efi Petinaki
We report the case of a 56-y-old male admitted with a left-sided post-pneumonic empyema. Clostridium sordellii DNA was directly detected in its pleural fluid by a broad-range 16S rRNA PCR, after 24 h of specimen collection. This is the third case of pleural infection caused by C. sordellii in the literature.
International Journal of Chronic Obstructive Pulmonary Disease | 2017
Eirini Stafyla; Theodora Kerenidi; Irini Gerogianni; Mary Geitona; Zoe Daniil; Konstantinos Gourgoulianis
Introduction The economic crisis in Greece has substantially affected patients with COPD. The reduction of disposable income has its consequences on patients’ ability to afford their medication. The aim of the study is to evaluate the cost of treatment for patients with COPD and the influence of the financial crisis to the patients. Methods Data were collected from 189 patients (male: 178, mean age: 70.1±8.4) who visited the outpatient department of University Hospital of Larissa in 2014 and 2015. The pharmacological cost of treatment was calculated based on national pharmaceutical formulary prices. Results COPD patients were classified into four stages according to Global Initiative for Chronic Obstructive Lung Disease (GOLD): 7.4% were in stage I, 43.4% in stage II, 34.4% in stage III, and 14.8% in stage IV. Patients were graded as per GOLD as follows: 18% as grade A, 14.3% as B, 23.3% as C, and 44.4% as D. The annual cost of COPD maintenance treatment per patient was €952.92 (±398.01), of which €239.91 were patients’ expenses. The annual treatment cost for stable disease ranged from €615.44 to €1302.03 depending on disease stages (GOLD stages I–IV) and from €715.01 to €1101.05 depending on GOLD grades (grades A–D). The cost of maintenance medication was statistically and significantly higher for patients with advanced disease (GOLD stages III–IV) and for patients at high risk (GOLD grades C–D [P=0.000]). Conclusion The pharmacological cost of treatment for COPD patients seems to be considerably high, in all disease stages. As the average income is decreased, patients face difficulties to afford inhaled medication.
Disease Markers | 2016
Kalliopi Aggelou; Elena Konstantina Siapati; Irini Gerogianni; Zoe Daniil; Konstantinos Gourgoulianis; Ioannis Ntanos; Emmanouel Simantirakis; Elias Zintzaras; Vassiliki Mollaki; George Vassilopoulos
Introduction. Tuberculosis (TB) is a major disease worldwide, caused by Mycobacterium tuberculosis (MTB) infection. The Toll-Like Receptor (TLR) pathway plays a crucial role in the recognition of MTB. Aim. The present study aimed to investigate the involvement of myeloid differentiation primary response protein 88 (MYD88) gene polymorphisms in TB. Materials and Methods. A total of 103 TB cases and 92 control subjects were genotyped for the MYD88 -938C>A (rs4988453) and 1944C>G (rs4988457) polymorphisms. Results. The MYD88 -938CA and -938AA genotypes were associated with an increased risk for tuberculosis with odds ratio (OR) of 5.71 (95% confidence intervals [CIs] 2.89–11.28, p = 0.01). Conclusions. The MYD88 -938C>A genetic polymorphism is associated with increased susceptibility to TB and may serve as a marker to screen individuals who are at risk.
Respiratory medicine case reports | 2017
Irini Gerogianni; Stylianos Boutlas; Theophilos Karachalios; Eythymia Petinaki; Marianna Vlychou; Kostas I. Gourgoulianis
Spondylodiscitis, the inflammation of the vertebral bodies and the intervertebral disk space, is the reason for low back pain in a minority of cases. This is caused by various pathogens. Mycobacterium tuberculosis is responsible for 17–39% of all the cases of spondylodiscitis. On the contrast, spondylodiscitis from non tuberculous mycobacteria is extremely rare in literature. We describe a 68 -year old diabetic woman which is the first case of bone marrow involvement by M. intracellulare (member of M avium complex)with spondylodiscitis.
Indian Journal of Medical Microbiology | 2014
Irini Gerogianni; S Gravas; Konstantinos Gourgoulianis; I Neonakis; Efthimia Petinaki
Intravesical instillation of Bacillus Calmette-Guerin (BCG) is the treatment of choice for superficial bladder carcinoma. Disseminated BCG infection presenting as granulomatous hepatitis or pneumonitis is a very rare complication of this treatment. Here we report a case series of seven patients previously treated with BCG presenting with pneumonitis. In two of the cases, identification of Mycobacterium bovis was achieved with molecular methods.